

+ Evidence in focus

Publication summary: McGinness K, et al. *Wounds* (2018)*

Use of STRAVIX[◇] Cryopreserved Umbilical Tissue achieved complete wound closure in diabetic patients with acute gas gangrene

+ Plus points

↓ 68.4%

mean wound area reduction at 4 weeks with STRAVIX Tissue

✓ 100%

of wounds achieved complete closure with STRAVIX Tissue

Overview

- A retrospective case series of 10 diabetic patients treated at a single center for acute lower extremity gas gangrene
- Wounds were complex with exposed bone, tendon or soft tissue, without adequate tissue for surgical closure (mean size post debridement, 45.9cm²)
- Patients received aggressive debridement and irrigation prior to covering wounds with a one-time application of STRAVIX Tissue, which was fenestrated and sutured/stapled to the skin edges
- Eight patients required metatarsal amputation and two required partial calcaneotomies
- Patients were treated with negative pressure wound therapy for 5–7 days post surgery (9/10 patients) and standard care until wounds closed

Results

- Patients were discharged from hospital after an average of 9 days
- At 4 weeks post surgery, the mean wound area reduction was 68.4% (Figure)
- All patients achieved complete wound closure with one STRAVIX Tissue application in a mean time of 13.4 weeks (range, 5–20 weeks; Figure)
- None of the patients required higher-level amputation




Figure. Mean wound area reduction (%) at 4 and 20 weeks, and the mean time to achieve complete wound closure

Conclusions

Use of STRAVIX Tissue helped all wounds to completely close and prevented the need for higher-level amputations in diabetic patients with acute gas gangrene. The authors noted that STRAVIX Tissue considerably reduced length of hospital stay compared with traditional inpatient treatment of gas gangrene.

Citation

*McGinness K, Kurtz Phelan DH. Use of viable cryopreserved umbilical tissue for soft tissue defects in patients with gas gangrene: A case series. *Wounds*. 2018;30(4):90–95.

Available at: [Wounds](#)

For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.